A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Phase 2
Recruiting
- Conditions
- Narcolepsy Type 1Narcolepsy Type 2Idiopathic Hypersomnia
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Centessa Pharmaceuticals (UK) Limited
- Target Recruit Count
- 78
- Registration Number
- NCT06752668
- Locations
- ๐บ๐ธ
Newton, Massachusetts, Newton, Massachusetts, United States
๐บ๐ธScottsdale, Arizona, Scottsdale, Arizona, United States
๐บ๐ธLong Beach, California, Long Beach, California, United States
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants with Advanced Solid Tumors
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Centessa Pharmaceuticals (UK) Limited
- Target Recruit Count
- 25
- Registration Number
- NCT05821777
- Locations
- ๐บ๐ธ
Sarah Cannon Research Institute at HealthONE., Denver, Colorado, United States
๐บ๐ธSarah Cannon Research Institute at Florida Cancer Specialists, Sarasota, Florida, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath